TUB-040
Solid tumors (e.g., ovarian, NSCLC) targeting NaPi2b
Phase 1Active
Key Facts
Indication
Solid tumors (e.g., ovarian, NSCLC) targeting NaPi2b
Phase
Phase 1
Status
Active
Company
About Tubulis Technologies
Tubulis Technologies is a private, clinical-stage biotech developing next-generation antibody-drug conjugates (ADCs) through its proprietary technology platforms. The company has advanced two in-house programs into clinical trials for solid tumors and is building a broader pipeline. With a strong scientific foundation and leadership team, Tubulis aims to overcome traditional ADC limitations, such as stability and payload scope, to create more effective and durable cancer therapies.
View full company profile